Norway Thrombosis And Hemostasis Biomarkers Market Size & Outlook
Norway thrombosis and hemostasis biomarkers market, 2018-2030 (US$M)
Related Markets
Norway thrombosis and hemostasis biomarkers market highlights
- The Norway thrombosis and hemostasis biomarkers market generated a revenue of USD 50.6 million in 2022 and is expected to reach USD 83.8 million by 2030.
- The Norway market is expected to grow at a CAGR of 6.5% from 2023 to 2030.
- In terms of segment, reagents & consumables was the largest revenue generating product in 2022.
- Reagents & Consumables is the most lucrative product segment registering the fastest growth during the forecast period.
Thrombosis and hemostasis biomarkers market data book summary
| Market revenue in 2022 | USD 50.6 million |
| Market revenue in 2030 | USD 83.8 million |
| Growth rate | 6.5% (CAGR from 2022 to 2030) |
| Largest segment | Reagents & consumables |
| Fastest growing segment | Reagents & Consumables |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Analyzers, Reagents & Consumables |
| Key market players worldwide | BioMerieux SA, Roche Holding AG, Siemens Healthineers AG ADR, Abbott Laboratories, Horiba Ltd, QuidelOrtho Corp, Thermo Fisher Scientific Inc, Biomedica Diagnostics, Werfen, Diazyme Laboratories |
Other key industry trends
- In terms of revenue, Norway accounted for 1.0% of the global thrombosis and hemostasis biomarkers market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany thrombosis and hemostasis biomarkers market is projected to lead the regional market in terms of revenue in 2030.
- France is the fastest growing regional market in Europe and is projected to reach USD 245.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Thrombosis And Hemostasis Biomarkers Market Scope
Thrombosis And Hemostasis Biomarkers Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway thrombosis and hemostasis biomarkers market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to thrombosis and hemostasis biomarkers market will help companies and investors design strategic landscapes.
Reagents & consumables was the largest segment with a revenue share of 65.02% in 2022. Horizon Databook has segmented the Norway thrombosis and hemostasis biomarkers market based on analyzers, reagents & consumables covering the revenue growth of each sub-segment from 2018 to 2030.
Norway has a high average life expectancy of 82 years. The country's increase in life expectancy over recent years and the consequently large aging population—prone to infectious and chronic diseases— are expected to support the demand for thrombosis and hemostasis biomarkers market.
A significant number of elderly people are living in Norway and many are suffering from heart related problems in the country, which is expected to boost the demand for diagnostics over the coming years.
Reasons to subscribe to Norway thrombosis and hemostasis biomarkers market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway thrombosis and hemostasis biomarkers market databook
-
Our clientele includes a mix of thrombosis and hemostasis biomarkers market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway thrombosis and hemostasis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Norway thrombosis and hemostasis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway thrombosis and hemostasis biomarkers market size, by product, 2018-2030 (US$M)
Norway Thrombosis And Hemostasis Biomarkers Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
